Fuse Medical, Inc. Announces Engagement of Montgomery, Coscia, Greilich, LLP – iCrowdNewswire
 
x

RSS Newsfeeds

See all RSS Newsfeeds

Global Regions

United States ( XML Feed )

Jan 11, 2018 6:10 PM ET

Fuse Medical, Inc. Announces Engagement of Montgomery, Coscia, Greilich, LLP

Disclosure NewswireTM

iCrowdNewswire - Jan 11, 2018

RICHARDSON, Texas –Fuse Medical, Inc., (OTC: FZMD), (“Fuse” or the “Company”), announced the appointment of Montgomery, Coscia, Greilich, LLP, (“MCG”), headquarter in Plano, Texas, as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2017.

“We are delighted with the expertise MCG brings to the table, and we believe that MCG’s in-depth capabilities closely align with our increasing larger economic footprint and strategic growth plans.”

Tweet this

The Company’s Board of Directors and management believe that MCG’s size and expertise more closely align with the strategic vision for the Company following the previously announced closing of the acquisition of CPM Medical Consultants, LLC on December 31, 2017.

Bill McLaughlin, Chief Financial Officer of Fuse, said, “We are delighted with the expertise MCG brings to the table, and we believe that MCG’s in-depth capabilities closely align with our increasing larger economic footprint and strategic growth plans.”

About Montgomery, Coscia, Greilich, LLP

MCG is a full-service professional accounting firm located in Plano, Texas. The firm offers traditional accounting services as well as transaction advisory, financial advisory, and strategy and management consulting. MCG provides a forward-looking audit strategy that focuses on risk and stakeholders’ needs and is designed to increase quality and efficiency in the financial statement reporting process. For more information, visit: https://www.mcggroup.com/.

About Fuse Medical, Inc.

Fuse provides a broad portfolio of orthopedic implants including internal and external fixation products; upper and lower extremity plating; total joint reconstruction; soft tissue fixation and augmentation for sports medicine procedures; full spinal implants for trauma, degenerative disc disease, and deformity indications; human allografts, substitute bone materials, and tendons; and regenerative tissues and fluids to augment orthopedic surgeries and wound care. For more information about Fuse, please visit: www.fusemedical.com.

Forward-Looking Statements

Certain statements in this press release, including those related to an anticipated purchase of all of the outstanding membership units and plans for the consolidated company, constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend,” or similar expressions or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based only on information available to the Company as of the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company’s filings with the Securities and Exchange Commission; the failure of the Company to close the transaction; and integration issues with the consolidated company. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events, or otherwise, except as required by law.

Contact Information:

Fuse Medical, Inc.
Devon Peddie, 469-862-3030
Investor Relations Analyst
Facsimile: 469-862-3035
[email protected]

View Related News >